Table 2 Clinical characteristics of patients related to exposure to MMF

Age

Sex (female)

54 (96.4%)

33 (94.3%)

17 (94.4%)

0.873

Ethnic background

0.408

 White

34 (60.7%)

18 (54.6%)

10 (55.6%)

 Black

4 (7.14%)

6 (18.2%)

4 (22.2%)

 Asian

13 (21.2%)

4 (12.1%)

3 (16.7%)

 Other

5 (8.93%)

5 (15.2%)

1 (5.56%)

Disease duration

18 (8, 17)

11 (7, 17)

8 (5, 13)

0.273

ACR criteria

 Malar rash

33 (58.9%)

17 (48.6%)

10 (55.6%)

0.626

 Discoid rash

7 (12.5%)

5 (14.3%)

3 (16.7%)

0.900

 Photosensitivity

37 (66.1%)

15 (42.9%)

7 (38.9%)

0.035

 Oral ulcers

38 (67.9%)

18 (51.4%)

12 (66.7%)

0.266

 Arthritis

49 (87.5%)

34 (97.1%)

14 (77.8%)

0.090

 Serositis

18 (32.1%)

9 (25.7%)

6 (33.3%)

0.772

 Neurological

4 (7.14%)

3 (8.57%)

1 (5.56%)

0.921

 Renal

21 (37.5%)

11 (31.4%)

12 (67.7%)

0.038

 Haematological

30 (53.6%)

22 (62.9%)

11 (61.1%)

0.651

 Immunological

39 (69.6%)

27 (77.1%)

15 (83.3%)

0.460

 ANA

49 (87.5%)

32 (91.4%)

15 (83.3%)

0.678

SLICC-DI

0 (0, 1)

0 (0, 2)

0 (0, 1)

0.862

Current prednisolone

46 (83.6%)

31 (88.6%)

17 (94.4%)

0.470

Daily prednisolone dose (mg/day)

10 (5–20)

10 (7.5–20)

10 (10–20)

0.280

SLEDAI score

10 (5.5–13.5)

6 (4–10)

10 (6–14)

0.051

Active disease (BILAG A/B)

 Constitutional (A or B)

6 (10.5%)

1 (2.86%)

1 (5.56%)

0.371

 Mucocutaneous (A or B)

33 (57.9%)

10 (28.6%)

8 (44.4%)

0.023

 Neuropsychiatric (A or B)

4 (7.02%)

4 (11.4%)

2 (11.1%)

0.735

 Musculoskeletal (A or B)

35 (61.4%)

10 (28.6%)

6 (33.3%)

0.004

 Cardiorespiratory (A or B)

8 (14.0%)

2 (5.71%)

3 (16.7%)

0.382

 Gastrointestinal (A or B)

3 (5.26%)

0

2 (11.1%)

0.172

 Ophthalmic (A or B)

2 (3.51%)

2 (5.71%)

1 (5.56%)

0.863

 Renal (A or B)

19 (33.3%)

9 (25.7%)

11 (61.1%)

0.034

 Haematological (A or B)

0

2 (5.71%)

1 (5.56%)

0.190

Low C3/C4

29 (51.2%)

11 (44.0%)

13 (72.2%)

0.173

Raised dsDNA

24 (42.9%)

12 (48.0%)

13 (72.2%)

0.094